Immutep Limited (IMMP)
Develops cancer immunotherapy drugs that boost the immune system to fight tumors.
$0.37-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-78.4%
The outlook
IMMP is trading near its 52-week lows, well below both its 50- and 200-day averages, reflecting weak recent momentum. Analyst coverage shows a notably bullish average price target about 304% above the current price, though the overall StockGlow score leans bearish. The wide gap between current price and target suggests either significant upside potential or substantial disagreement among analysts.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range3% of the way from its 52-week low to high
Price targetAvg target +304% vs current price
Market cap
$54.7M
52-wk high
$3.53
52-wk low
$0.29
50-day avg
$0.42
200-day avg
$1.51
Trailing P/E
—